- Home
- MGNI vs AKRO Comparison
MGNI vs AKRO Comparison
Compare MGNI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- AKRO
- Stock Information
- Founded
- MGNI 2007
- AKRO 2017
- Country
- MGNI United States
- AKRO United States
- Employees
- MGNI N/A
- AKRO N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- AKRO Health Care
- Exchange
- MGNI Nasdaq
- AKRO Nasdaq
- Market Cap
- MGNI 2.4B
- AKRO 3.9B
- IPO Year
- MGNI N/A
- AKRO 2019
- Fundamental
- Price
- MGNI $22.69
- AKRO $51.69
- Analyst Decision
- MGNI Strong Buy
- AKRO Strong Buy
- Analyst Count
- MGNI 13
- AKRO 6
- Target Price
- MGNI $21.54
- AKRO $82.50
- AVG Volume (30 Days)
- MGNI 3.3M
- AKRO 1.6M
- Earning Date
- MGNI 08-06-2025
- AKRO 08-08-2025
- Dividend Yield
- MGNI N/A
- AKRO N/A
- EPS Growth
- MGNI N/A
- AKRO N/A
- EPS
- MGNI 0.21
- AKRO N/A
- Revenue
- MGNI $674,622,000.00
- AKRO N/A
- Revenue This Year
- MGNI $0.32
- AKRO N/A
- Revenue Next Year
- MGNI $11.02
- AKRO N/A
- P/E Ratio
- MGNI $105.79
- AKRO N/A
- Revenue Growth
- MGNI 5.59
- AKRO N/A
- 52 Week Low
- MGNI $8.22
- AKRO $21.34
- 52 Week High
- MGNI $25.27
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MGNI 64.93
- AKRO 45.35
- Support Level
- MGNI $23.25
- AKRO $50.13
- Resistance Level
- MGNI $25.27
- AKRO $53.60
- Average True Range (ATR)
- MGNI 0.99
- AKRO 2.03
- MACD
- MGNI -0.05
- AKRO -0.83
- Stochastic Oscillator
- MGNI 64.99
- AKRO 6.37
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.